Bruna Pellini: Are all immune checkpoint inhibitors the same?
“Are all immune checkpoint inhibitors (ICIs) the same?
Our hot off the press pub on SCLC suggests they are NOT.”
“In a recent retrospective study Zou et al compared the efficacy and safety of atezolizumab vs. durvalumab + chemo for pts with ES-SCLC in China and found patients treated with Durvalumab had a mOS of 22 mo vs. 10 mo with atezolizumab. This motivated us to conduct a similar study at Moffitt Cancer Center.”
“In our retrospective study in Extensive Stage SCLC 101 patients were included and patients treated with Durvalumab had a superior OS of 14.7 months vs. 11.6 months with Atezolizumab.”
Congrats to our mentee Megan Vince that led this study!”
Authors: Megan Vince, et al.
Bruna Pellini is an Assistant Professor at the University of South Florida and an Assistant Member in the Department of Thoracic Oncology at Moffitt Cancer Center. Her research centers on the use of liquid biopsies to monitor treatment response, detect minimal residual disease (MRD), and integrate these techniques into clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023